HC Wainwright Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2025 earnings at $1.36 EPS, FY2026 earnings at $2.25 EPS, FY2027 earnings at $3.14 EPS and FY2028 earnings at $6.05 EPS.

A number of other analysts have also commented on ESPR. StockNews.com raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Needham & Company LLC dropped their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $2.28 on Friday. Esperion Therapeutics has a one year low of $0.87 and a one year high of $3.40. The company has a market cap of $447.39 million, a price-to-earnings ratio of -3.56 and a beta of 0.96. The firm has a 50 day simple moving average of $1.91 and a 200 day simple moving average of $2.13.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. As a group, analysts expect that Esperion Therapeutics will post -0.09 EPS for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the stock. BOKF NA acquired a new position in shares of Esperion Therapeutics in the second quarter worth approximately $26,000. Traphagen Investment Advisors LLC bought a new position in Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. acquired a new position in shares of Esperion Therapeutics in the 2nd quarter worth approximately $28,000. CVI Holdings LLC bought a new stake in shares of Esperion Therapeutics in the 1st quarter valued at $37,000. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth $44,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.